John P. Butler - Feb 28, 2022 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Role: CEO and President, Director
Signature: /s/ Carolyn Rucci, attorney-in-fact for John P. Butler
Stock symbol: AKBA
Transactions as of: Feb 28, 2022
Transactions value $: -$171,143
Form type: 4
Date filed: 3/2/2022, 08:25 PM
Previous filing: Aug 5, 2021
Next filing: Jun 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKBA	Common Stock	Sale	-$54K	-25.1K	-2.11%	$2.15	1.16M	Feb 28, 2022	Direct	F1, F2
transaction	AKBA	Common Stock	Award	$0	+293K	+25.18%	$0.00	1.46M	Feb 28, 2022	Direct	F3
transaction	AKBA	Common Stock	Sale	-$53.9K	-24.8K	-1.7%	$2.17	1.43M	Mar 1, 2022	Direct	F4
transaction	AKBA	Common Stock	Sale	-$54.3K	-25K	-1.75%	$2.17	1.41M	Mar 1, 2022	Direct	F5
transaction	AKBA	Common Stock	Sale	-$8.97K	-4.13K	-0.29%	$2.17	1.4M	Mar 1, 2022	Direct	F6
holding	AKBA	Common Stock						59.9K	Feb 28, 2022	Held by Dorothy Butler 2019 GRAT
holding	AKBA	Common Stock						100K	Feb 28, 2022	Held By Dorothy Butler GRAT November 2019
holding	AKBA	Common Stock						59.9K	Feb 28, 2022	Held by John Butler 2019 GRAT
holding	AKBA	Common Stock						100K	Feb 28, 2022	Held By John Butler GRAT November 2019

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKBA	Employee Stock Option (Right to buy)	Award	$0	+740K		$0.00	740K	Feb 28, 2022	Common Stock	740K	$2.16	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
F2	Includes: (i) the 1,248 shares of common stock that were described in the amendment on Form 4/A filed by the reporting person with the SEC on February 18, 2022, (ii) 1,500 shares of the Issuer's common stock purchased on each of June 30, 2021 and December 31, 2021, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan, and (iii) 32,747 shares of common stock that represent a change from indirect to direct ownership of shares previously reported as beneficially owned by the reporting person.
F3	The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. One-third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
F4	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
F5	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2019.
F6	This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.
F7	The options were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date.